"Indinavir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.
| Descriptor ID |
D019469
|
| MeSH Number(s) |
D03.383.725.385
|
| Concept/Terms |
L-735 524- L-735 524
- L 735 524
- L735 524
- L-735,524
- L 735,524
- L735,524
|
Below are MeSH descriptors whose meaning is more general than "Indinavir".
Below are MeSH descriptors whose meaning is more specific than "Indinavir".
This graph shows the total number of publications written about "Indinavir" by people in this website by year, and whether "Indinavir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 1 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Indinavir" by people in Profiles.
-
Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CLpro through high-throughput virtual screening and molecular dynamics simulation. Aging (Albany NY). 2021 03 07; 13(5):6258-6272.
-
Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach. J Infect Public Health. 2020 Dec; 13(12):1856-1861.
-
Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics simulation. Sci Rep. 2020 10 12; 10(1):16986.
-
A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med Infect Dis. 2020 May - Jun; 35:101646.
-
a7-Nicotinic acetylcholine receptor inhibition by indinavir: implications for cognitive dysfunction in treated HIV disease. AIDS. 2017 05 15; 31(8):1083-1089.
-
Prevention of vaginal simian immunodeficiency virus transmission in macaques by postexposure prophylaxis with zidovudine, lamivudine and indinavir. AIDS. 2009 Feb 20; 23(4):447-54.
-
Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis. 2004 Mar 15; 189(6):1056-74.
-
HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS. 2003 Mar 07; 17(4):513-20.
-
Indinavir in cerebrospinal fluid of HIV-1-infected patients. Lancet. 1997 Dec 20-27; 350(9094):1823.
-
Remission of AIDS-associated intestinal microsporidiosis with highly active antiretroviral therapy. AIDS. 1997 Nov; 11(13):1658-9.